In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on Galectin Therapeutics GALT.
In the report, MLV & Co noted, “Albeit from 8 patients, an abundance of data support the safety and positive effects of GR-MD-02 on the major pathological processes observed in NASH. Next steps include dosing at 4mg/kg, adding FibroScan, an FDA-approved ultrasonic measure of liver tissue elasticity, to cohort 2 protocol. We continue to expect positive results in cohort 2 (expected Jul-Aug 2014).”
Galectin Therapeutics closed on Monday at $15.31.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in